A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

Ruperto, N; Murray, KJ; Gerloni, V; Wulffraat, N; de Oliveira, SKF; Falcini, F; Dolezalova, P; Alessio, M; Burgos-Vargas, R; Corona, F; Vesely, R; Foster, H; Davidson, J; Zulian, F; Asplin, L; Baildam, E; Consuegra, JG; Ozdogan, H; Saurenmann, R; Joos, R; Pistorio, A; Woo, P; Martini, A

doi:10.1002/art.20288

A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate

Atıf İçin Kopyala

Ruperto N., Murray K., Gerloni V., Wulffraat N., de Oliveira S., Falcini F., ...Daha Fazla

ARTHRITIS AND RHEUMATISM, cilt.50, sa.7, ss.2191-2201, 2004 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 50 Sayı: 7
Basım Tarihi: 2004
Doi Numarası: 10.1002/art.20288
Dergi Adı: ARTHRITIS AND RHEUMATISM
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2191-2201
İstanbul Üniversitesi Adresli: Hayır

Özet

Objective. To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15mg/m(2)/week) versus a higher dosage (30 mg/m(2)/ week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/ week).